OrbiMed’s KALA BIO KALA Stock Holding History

OrbiMed’s Portfolio KALA Stock Details KALA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,377	Closed	-$9.01M	–	164
2021 Q3	$9.01M	Sell	1,377 -811	-37%	-$7M	0.1%	132
2021 Q2	$29M	Hold	2,188	–	–	0.29%	79
2021 Q1	$36.8M	Hold	2,188	–	–	0.34%	73
2020 Q4	$37.1M	Hold	2,188	–	–	0.32%	74
2020 Q3	$41M	Buy	2,188 +25	+1%	+$575K	0.52%	57
2020 Q2	$56.8M	Hold	2,163	–	–	0.8%	38
2020 Q1	$47.5M	Buy	2,163 +782	+57%	+$12.5M	0.8%	40
2019 Q4	$12.7M	Hold	1,381	–	–	0.18%	75
2019 Q3	$13.1M	Hold	1,381	–	–	0.25%	74
2019 Q2	$22M	Hold	1,381	–	–	0.34%	68
2019 Q1	$28.5M	Hold	1,381	–	–	0.44%	57
2018 Q4	$16.9M	Hold	1,381	–	–	0.31%	72
2018 Q3	$34M	Hold	1,381	–	–	0.41%	67
2018 Q2	$47.3M	Hold	1,381	–	–	0.56%	53
2018 Q1	$54.6M	Buy	1,381 +430	+45%	+$16.3M	0.68%	49
2017 Q4	$43.9M	Hold	951	–	–	0.56%	54
2017 Q3	$54.3M	Buy	+951	New	+$52.2M	0.52%	61

Other funds holding KALA

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VAFP

Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

OrbiMed's KALA Position: Q4 2021 in Review

OrbiMed sold out of KALA BIO (KALA) in Q4 2021, closing a stake of 1,377 shares — an estimated $9.01M sold.

OrbiMed first reported a position in KALA in Q3 2017 and held it in 17 quarters. The position peaked at $56.8M in Q2 2020. 79 funds tracked by Wall St. Rank hold KALA as of Q4 2021.

OrbiMed reported no remaining KALA BIO position as of Q4 2021 after selling out during the quarter.
OrbiMed sold 1,377 KALA BIO shares in Q4 2021, an estimated $9.01M.
OrbiMed first reported a position in KALA BIO in Q3 2017 and held it in 17 quarters.
OrbiMed's KALA BIO position peaked at $56.8M in Q2 2020.
79 funds tracked by Wall St. Rank held KALA BIO as of Q4 2021.

Based on OrbiMed's 13F filing for Q4 2021, filed 14 Feb 2022.